Remove 2025 Remove Litigation Remove Patent
article thumbnail

EMP&A Accepting Summer 2025 Intern Applications

Erik K Pelton

We are seeking a law student for a paid IP/Trademark internship ($25/hr) from May 2025 to August 2025 (dates are flexible, minimum 10 weeks is required). Applications will be accepted through February 28, 2025. The post EMP&A Accepting Summer 2025 Intern Applications appeared first on Erik M Pelton & Associates, PLLC.

article thumbnail

The Impact of Prosecution Length on Invalidity Outcomes in Patent Litigation

JD Supra Law

This Article analyzes over 89,000 patents litigated over a twenty-year period to determine how the number of office actions to allowance during prosecution impacts rates of invalidity during subsequent litigation. Originally published in volume 38, issue 1 of the Harvard Journal of Law & Technology, February 2025.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Hatch-Waxman Litigation Expenses Are Deductible Under Internal Revenue Code § 162(a)

JD Supra Law

21, 2025) (Chen, Cunningham, Stark, JJ.). Actavis Labs. United States, Case No. 23-1320 (Fed.

article thumbnail

Spotlight On: Enbrel® (etanercept) / Erelzi® (etanercept-szzs) / Eticovo® (etanercept-ykro) - March 2025

JD Supra Law

Etanercept Challenged Claim Types in IPR and Litigation: Claims include those challenged in litigations and IPRs. Claims are counted in each litigation and IPR, so claims from the same patent challenged in multiple litigations/IPRs are counted more than once. Within each litigation a claim is counted only once.

article thumbnail

Fintiv and the Resurgence of PTAB Discretionary Denials Involving the ITC

JD Supra Law

On March 24, 2025, the United States Patent and Tradmark Office (USPTO) issued a new Memorandum providing guidance on discretionary denials (or Fintiv denials) for inter partes review (IPR) challenges based on co-pending patent litigation.

article thumbnail

Spotlight On: Rituxan® (rituximab) / Truxima® (rituximab-abbs) / Ruxience® (rituximab-pvvr) / Riabni™ (rituximab-arrx) - March 2025

JD Supra Law

Rituximab Challenged Claim Types in IPR and Litigation: Claims include those challenged in litigations and IPRs. Claims are counted in each litigation and IPR, so claims from the same patent challenged in multiple litigations/IPRs are counted more than once. Within each litigation a claim is counted only once.

article thumbnail

PTAB Recalibrates Review: New Discretionary Denial Framework and Pre-Institution Reform

JD Supra Law

In less than a month, the United States Patent and Trademark Office (USPTO) has dramatically reformed its policies and procedures for exercising its discretion to deny institution of AIA post-grant proceedings. By: Hudnell Law Group